Partnering with Calico
Calico’s mission is to understand the biology that controls lifespan. We will use that knowledge to devise interventions that enable people to lead longer and healthier lives. We have assembled an outstanding team of scientists with diverse backgrounds and expertise in biology, aging, medicine, genetics, machine learning and informatics, and drug development. In addition to Calico’s internal efforts, executing on this mission will require collaborations and partnerships with the leading academic institutions and biotechnology companies that share our vision. We recognize that many great ideas will come from the vast research community beyond Calico and that effective collaborations will be critical to achieving success.
Why Collaborate with Calico
Calico combines the focus and drive of a startup with the resources and world-class R&D capabilities of the leading pharmaceutical companies. Our leadership has one of the most successful track records in the industry for supporting basic research and translating novel findings to bring innovative therapeutics to market. We have invested heavily in research infrastructure necessary to perform cutting-edge science (including state-of-the-art sequencing, computational biology and machine learning, metabolomics/proteomics, microscopy/imaging, and translational biology). Through our productive collaboration with AbbVie we have outstanding access to resources including medicinal chemistry, protein production, drug screening, and structural biology to accelerate the development of therapeutic programs and discovery technologies. Our bar is high, but by combining our passion for outstanding science with proven development expertise and capabilities, we are confident that Calico will be an outstanding partner to advance promising collaborative programs successfully. We envision initiating several new collaborations each year.
Calico’s Areas of Interest
Calico’s areas of interest are organized around understanding the basic biology of aging as well as interventions for serious age-related diseases. Calico is exploring the genetics of aging in human populations as well as in a variety of model organisms from yeast to worms to naked mole rats. Beyond genetics, we are focused on the hallmarks of aging including proteostasis, stress responses, cellular energetics and senescence. Therapeutic areas of key interest for Calico include oncology, neurodegeneration, chronic inflammation and metabolic dysfunction because the incidence of these conditions rises sharply in advanced age and is associated with great morbidity. We also believe that, in some cases, programs focused on patients with rare diseases may present unique opportunities to explore aging biology in the context of therapeutic development. We are most interested in external opportunities at the research and early development stage within these areas of focus.
Calico believes that successfully advancing our mission will also require access to cutting-edge technologies and state-of-the-art tools and infrastructure. We actively seek novel discovery platforms in the areas of DNA sequencing and phasing, mass spectrometry, imaging, machine learning and computation, to name a few.
Types of Collaborations
Calico is flexible regarding how we structure our partnerships. Our preference is to be deeply engaged scientifically in collaborative research programs. Our collaborations range from sponsored academic research with leading investigators for early stage projects to licensing and collaboration agreements on clinical-stage therapeutic programs and drug discovery platforms. We have executed a number of significant collaborations since our inception (see link here).
If you would like to collaborate with Calico, please provide us with a non-confidential proposal that describes the opportunity, including scientific supporting data to: